Sameer S. Kadri, MD, MS

MD, Seth G.S. Medical College
MS, Harvard School of Public Health

Dr. Kadri earned his degree in Medicine from the Seth G. S. Medical College and King Edward Memorial Hospital in Mumbai, India. He trained in Internal Medicine at the New York-Presbyterian/Weill Cornell Medical Center, Infectious Diseases at the Massachusetts General Hospital, in Critical Care at the NIH Clinical Center and in Clinical Epidemiology at the Harvard T.H. Chan School of Public Health.

Dr. Kadri was recently awarded tenure and appointed to Senior Investigator in 2026 in the NIH Clinical Center's Critical Care Medicine Department at the NIH Clinical Center. In this role, he splits his time between attending in the ICU, serving as an NIH principal investigator, supervising a data Lab, and training fellows. Prior to this he held positions of Staff Clinician (2014-2021) and Tenure Track Investigator (2021-2026) within the same department.

His primary research interest lies in identifying clinical and public health strategies to improve patient outcomes in acute illness through real world evidence. He leverages large clinical and administrative datasets to generate insights through innovative epidemiologic investigations on a diverse array of high mortality conditions. These include therapeutically challenging conditions such as antimicrobial resistant infections and sepsis and operationally challenging conditions such as hospital overcrowding in public health emergencies and everyday care to inform clinical care and health policy. Dr Kadri's lab has contributed several landmark investigations to help improve care delivery and outcomes in disasters and public health emergencies that helped enable large-scale operational changes in patient management during the pandemic. This includes studies showcasing the detrimental impact of hospital overcrowding, the safety in moving patients with respiratory failure between hospitals, and the impact of centralizing transfer coordination on transfer rates.

He founded and leads the NIH Antimicrobial Resistance Outcomes Research Initiative (NIH–ARORI), an interagency and extramural collaborative. He developed and tested a novel classification scheme for antimicrobial resistance called "Difficult-to-treat Resistance" or DTR that focuses on non-susceptibility to all first-line antibiotics. His group has performed studies comparing the real-world effectiveness of antibiotics used to treat infections for which clinical trials and unfeasible and unlikely. His lab collaborates closely with other federal agencies and several University-based investigators. Dr. Kadri has been awarded several NIH intramural grants including RASCL and Director's Challenge grants and received non-NIH grant funding. He has won several research, mentorship, and early investigator awards and other accolades from professional societies for his work.

Dr. Kadri has authored over 135 peer-reviewed publications and has held various editorial positions over the years. He has mentored several clinician scientists who have gone on to secure independent funding and prestigious academic positions. He has served on several scientific review committees, technical expert panels, and on CDC and National Academies of Sciences, Engineering and Medicine-led initiatives.

• 2025 IDSA Oswald Avery Award for Early Achievement
• 2025 Invited to National Academies of Medicine Emerging Leaders Forum
• 2024 NIH Director's Ruth Kirschstein Award for mentoring excellence
• 2024 NIH Director's Challenge Grant Award
• 2024 NHLBI Director's Award on COVID-19 Response
• 2024 Honorary induction as fellow to American College of Physicians
• 2022 Harvard Chan Emerging Public Health Professional Award
• 2022 NIH Director's Award for Outstanding Accomplishment
• 2021 NIH Clinical Center CEO Award for Science
• 2019 Inducted as Fellow to the Infectious Diseases Society of America
• 2018 NIH Clinical Center CEO Award for Accomplishments in Clinical Epidemiology
• 2018 Society of Critical Care Medicine Star Research Gold Medal Award
• 2017 Society of Critical Care Medicine Star Research Achievement Award

Kadri SS, Sun J, Lawandi A, Strich JR, Busch LM, Keller M, Babiker A, Yek C, Malik S, Krack J, Dekker JP, Spaulding AB, Ricotta E, Powers JH 3rd, Rhee C, Klompas M, Athale J, Boehmer TK, Gundlapalli AV, Bentley W, Datta SD, Danner RL, Demirkale CY, Warner S. Association Between Caseload Surge and COVID-19 Survival in 558 U.S. Hospitals, March to August 2020. Ann Intern Med. 2021 Sep;174(9):1240-1251. doi: 10.7326/M21-1213.

Kadri SS, Lai YL, Warner S, Strich JR, Babiker A, Ricotta EE, Demirkale CY, Dekker JP, Palmore TN, Rhee C, Klompas M, Hooper DC, Powers JH 3rd, Srinivasan A, Danner RL, Adjemian J; forming the National Institutes of Health Antimicrobial Resistance Outcomes Research Initiative (NIH-ARORI). Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals. Lancet Infect Dis. 2021 Feb;21(2):241-251. doi: 10.1016/S1473-3099(20)30477-1.

Neupane M, Warner S, Mancera A, Sun J, Yek C, … Kadri, SS. Association between Hospital Type and Resilience during Caseload Stress: A Natural Quality-of-Care Experiment from the COVID-19 Pandemic. Ann Intern Med. 2024 Oct;177(10):1370-1380.

Sarzynski SH, Mancera A, Mann C, Dai M, Sun J, … Kadri SS. Frequency and Risk of Emergency Medical Service Interhospital Transportation of Patients with Acute Lower Respiratory Tract Illness During the COVID-19 Pandemic in the US. JAMA. 2022 Mar 1;327(9):874-877. doi: 10.1001/jama.2022.0812. PMID: 35089309; PMCID: PMC8889457.

Kadri SS, Gundrum J, Warner S, Cao Z, Babiker A, Klompas M, Rosenthal N. Uptake and Accuracy of the Diagnosis Code for COVID-19 Among US Hospitalizations. JAMA. 2020 Dec 22;324(24):2553-2554. doi: 10.1001/jama.2020.20323. PMID: 33351033; PMCID: PMC7756233.

Richert ME, Diao G, Mancera A, Badesch B, Neupane M, ... Kadri SS. Statewide Transfer Coordination and Patient Transfer Rates Among Hospitals During Occupancy Stress. JAMA Netw Open. 2025 Dec 1;8(12):e2546002. doi: 10.1001/jamanetworkopen.2025.46002. PMID: 41324958; PMCID: PMC12670198.

Babiker A, Warner S, Li X, Chishti EA, Saad E, Swihart BJ, Dekker JP, Walker M, Lawandi A, Kadri SS; NIH-Antimicrobial Resistance Outcomes Research Initiative. Adjunctive linezolid versus clindamycin for toxin inhibition in β-lactam-treated patients with invasive group A streptococcal infections in 195 US hospitals from 2016 to 2021: a retrospective cohort study with target trial emulation. Lancet Infect Dis. 2025 Mar;25(3):265-275. doi: 10.1016/S1473-3099(24)00507-3. Epub 2024 Oct 10. Erratum in: Lancet Infect Dis. 2024 Dec;24(12):e737. doi: 10.1016/S1473-3099(24)00732-1. PMID: 39396526; PMCID: PMC11871996.

Kadri SS, Adjemian J, Lai YL, Spaulding AB, Ricotta E, Prevots DR, Palmore TN, Rhee C, Klompas M, Dekker JP, Powers JH 3rd, Suffredini AF, Hooper DC, Fridkin S, Danner RL; National Institutes of Health Antimicrobial Resistance Outcomes Research Initiative (NIH–ARORI). Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents. Clin Infect Dis. 2018 Nov 28;67(12):1803-1814. doi: 10.1093/cid/ciy378.

Kadri SS, Boucher HW. U.S. Efforts to Curb Antibiotic Resistance - Are We Saving Lives? N Engl J Med. 2020 Aug 27;383(9):806-808. doi: 10.1056/NEJMp2004743. PMID: 32846058.

Visit PubMed.gov for a full list of Dr. Kadri's publications.